Absolute Quantification in Bone Scintigraphy

NCT ID: NCT04671238

Last Updated: 2022-09-13

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

21 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-01-01

Study Completion Date

2021-02-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

While absolute quantification in 18F-FDG PET (Positon Emission Tomography) is widely used in clinical routine, absolute quantification in SPECT (Single Photon Emission Computed Tomography) is under development and its clinical interest remains to be demonstrated. Recent studies carried out on bone scan recordings show the potential interest of quantification indexes such as SUV (Standard Uptake Value).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

In oncology, bone scan studies have reported significantly higher SUV values for secondary bone lesions compared with benign osteoarticular lesions , and some have even defined an SUVmax threshold value that points to prostatic bone metastases.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Scintigraphy Quantification

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patient for SPECT/CT scan

Patients referred for SPECT/CT scan of the spine as part of a vertebroplasty workup and selected retrospectively.

SPECT CT

Intervention Type DEVICE

SPECT/CT scan of the spine as part of a vertebroplasty

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

SPECT CT

SPECT/CT scan of the spine as part of a vertebroplasty

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with recent vertebral fractures:

1. who have had at least two SPECT/CT scan scans of the spine as part of a pre-vertebroplasty check-up,
2. for which fracture dates were known.

Exclusion Criteria

1. Minor person
2. Person opposing the use of their data (Posters in waiting rooms explaining that the patient must object if they do not wish their data to be used)
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Central Hospital, Nancy, France

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Pierre Yves MARIE

Study director

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

BALHOUL Achraf, MD

Role: PRINCIPAL_INVESTIGATOR

CHRU of Nancy

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

CHU de Nancy - Hôpital Brabois

Vandœuvre-lès-Nancy, , France

Site Status

Chru Nancy

Vandœuvre-lès-Nancy, , France

Site Status

CHRU of Nancy

Vandœuvre-lès-Nancy, , France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2020PI241

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.